Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion

This article was originally published in The Pink Sheet Daily

Executive Summary

HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.

You may also be interested in...



Novartis/HGS’ Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C

Question now is whether the long-acting version of interferon will be able to make a “me-better” case based on dosing and quality of life benefits.

Novartis/HGS’ Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C

Question now is whether the long-acting version of interferon will be able to make a “me-better” case based on dosing and quality of life benefits.

Novartis/HGS' Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C

Solid results from the first of two key Phase III trials for Novartis/Human Genome Sciences’ hepatitis C candidate Albuferon (albinterferon alfa-2b) reduce the pressure by alleviating an earlier pulmonary safety concern, but the question remains whether quality of life and dosing benefits are enough for Albuferon to make headway in the interferon market.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel